search
Back to results

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein (Gen3)

Primary Purpose

Absorption; Disorder, Protein, Protein Malabsorption, Protein Intolerance

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Genepro Generation 3 Protein
Whey Protein
Sponsored by
Musclegen Research, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Absorption; Disorder, Protein focused on measuring protein, absorption

Eligibility Criteria

25 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA:

  • Participants will be solicited to volunteer through WakeMed Bariatric Surgery Center (current patients)
  • All participants must have normal blood protein levels prior to the study
  • All participants must be six months post op (bariatric surgery)
  • All participants must avoid any other protein supplementation during the trial period
  • All participants are required to maintain a daily nutrition log
  • All participants must have no milk/dairy allergies
  • Age Eligibility: 25 years to 80 years (Adult)
  • Sexes Eligibility for Study: ALL
  • Only Accepts Healthy Volunteers

EXCLUSION CRITERIA:

  • No candidates with prior digestive distress disorders (IBS, Crones, etc.)
  • Participants with any negative GI score, they will be excluded from the study
  • Participants with abnormal blood protein levels at the time of study
  • Unhealthy Volunteers
  • Volunteers with compromised immune systems
  • Volunteers younger than 25 years of age
  • Volunteers older than 80 years of age
  • Allergies to milk or lactose

Sites / Locations

  • WakeMed Bariatric Surgery CenterRecruiting
  • WakeMed

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Genepro Generation 3

Whey Protein

Arm Description

1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.

1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.

Outcomes

Primary Outcome Measures

Blood Protein Levels
Each participant in each group will have blood protein levels checked via blood draw at a WakeMed facility (based on participants geographic location). The target blood protein range is 6.1-8.7 g/dL this test is administered without fasting.

Secondary Outcome Measures

Full Information

First Posted
October 22, 2020
Last Updated
November 9, 2020
Sponsor
Musclegen Research, Inc.
Collaborators
WakeMed Bariatric Surgery & Weight Loss Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04615858
Brief Title
Genepro Generation 3 Protein Bioavailability Compared to Whey Protein
Acronym
Gen3
Official Title
Genepro Generation 3 Bioavailability Compared to Whey Protein (12g Genepro vs 30g Whey)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2020 (Anticipated)
Primary Completion Date
January 26, 2021 (Anticipated)
Study Completion Date
February 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Musclegen Research, Inc.
Collaborators
WakeMed Bariatric Surgery & Weight Loss Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objective of Clinical Trial: To test, in a blinded study the bioavailability of Genepro Generation 3 (GEN3) Protein as compared to whey protein. This study is intended to show the equivalent value of Genepro Gen3 as compared to whey protein (1scoop (12g) Genepro Generation 3 (GEN3) compared to 30g serving of whey protein). Total Serum Protein levels will be tested every other week to evaluate blood protein levels in each participant
Detailed Description
Detailed Description: Condition or Disease: Analysis, Event History. Absorption; Disorder, protein Objective of Clinical Trial: To test, in a blinded study the bioavailability of Genepro Generation 3 (GEN3) Protein as compared to whey protein. This study is intended to show the equivalent value of Genepro Gen3 as compared to whey protein (1scoop (12g) Genepro Generation 3 (GEN3) compared to 30g serving of whey protein). Total Serum Protein levels will be tested every other week to evaluate blood protein levels in each participant. Parameters: This study encompasses a 6-week program that follows 40 gastric bypass patients that have undergone weight loss surgery. We will establish a baseline blood analysis prior to the start of the study and subsequently we will take bi-weekly blood work to chart and register the findings (weeks 2, 4 and 6). For this study we will only be doing the bi-weekly analysis on blood protein levels by utilizing Spectrophotometry with total serum protein. The target blood protein range is 6.1-8.7 g/dL this test is administered without fasting. Participants: 40 Post Op Gastric Bypass patients. 20 men, 20 women. All participants were between the ages of 25-80 years of age. All participants have been post operation from their weight loss surgery for a minimum of 6 months prior to the start of the study and no longer than 8 months at the start of the study. Participants will be randomly selected, blindly, by the study sponsor. The selection will utilize participants files with names and ethnicity removed. Selection will be randomized into Group A and Group B. One group will be assigned Genepro while the other group will be assigned a leading whey protein powder. Participants will be assigned a Identification Code/Number for the duration of the study. Results will be posted using this identification number as well as stating the age and gender of the participant. Participant names will be held in confidence. Participants must maintain a daily log that will be shared with study investigators. This log will contain daily lists of food and beverage consumed as well as personal thoughts on taste and ease of use of protein supplements as well as a daily synopsis of overall general emotional and physical feelings. Participant Compensation: Three (3) thirty serving units of Genepro Generation 3 at the conclusion of the study. Gathering Results: 40 subjects will receive Genepro Generation 3 protein (12g serving) for one week prior to the study as well as all 6 weeks of the study. In conjunction the other group of 20 subjects will receive 30g whey protein for one week prior to the study as well as all 6 weeks of the study. Bi-Weekly blood analysis will determine blood protein levels. Blood draws are to be conducted at a WakeMed facility (Cary, NC or Raleigh, NC - determined by the proximity to the patient for their convenience). Results will be submitted for review and entry from WakeMed to the sponsor oversight POC every 2 weeks. To ensure proper transfer of data, WakeMed will keep and store all lab reports/results for a minimum of 2 years after the conclusion of the study. Soft copies will be inserted into a virtual storage center to be maintained and accessible by both, the sponsor as well as the medical partners. Diet: Diet guidelines limit the calories you consume while providing you with balanced meals to help prevent nutritional deficiencies and preserve your muscle tissue. Each patient tolerates suggested foods differently. Daily calories should be between 600 to 700 for the duration of this study. Each subject is to follow a diet low in calories, fats and sweets. The goal for each subject is to consume a minimum of 65 to 75 grams of protein a day. High protein foods include eggs, meats, fish, seafood, tuna, poultry, tofu, milk, soy, cottage cheese, and yogurt. 30g of each daily intake of protein will be provided by a powdered protein supplement. 20 subjects will utilize a 30g serving of whey protein for 1 week prior to the study as well as 6 weeks of the study. The other group of 20 subjects will use a single serving (12g) of Genepro Gen3 Protein over the same duration. Subject were given the following eating guidelines: Eat slowly and chew small bites of food thoroughly. Avoid rice, bread, raw vegetables, fresh fruits, and meats that are not easily chewed such as pork and steak. Ground meats are usually better tolerated. With soft and solid foods, take only three bites at one sitting, then wait a minimum of 20 minutes before eating more. Eat balanced meals with small portions. Avoid the use of drinking straws and carbonated beverages, chewing gum and ice because they can introduce too much air into your pouch and cause discomfort. Avoid sugar, sugar-containing foods and beverages, concentrated sweets, and fruit juices Alcoholic beverages will have a more profound effect and should be avoided or consumed with caution. Storage and Distribution of Protein Powder: WakeMed Clinical Oversight Manager and Principal Investigator, Marina Maddaloni, will be provided with a lockable storage container to be positioned in her personal office. WakeMed will be provided white and black containers. One color will house either Genepro or regular Whey protein. WakeMed will not have knowledge of which color container holds which protein powder to ensure that the distribution to participants is totally blinded. Participants will be given enough protein supplementation, either regular whey or Genepro Generation 3 protein, to last the duration of the study. Peer Reviewer 1: Dr. Brian M. Parks Peer Reviewer 2: Zac Cain Non-Peer Review: Dr. Jon Bruce

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Absorption; Disorder, Protein, Protein Malabsorption, Protein Intolerance
Keywords
protein, absorption

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Masking Description
Active Comparator: Genepro Gen2 Protein 11g Serving of Genepro Gen3 Protein daily will be used in each subject. Intervention: Bi-Weekly blood draws will determine the effect on blood protein levels. Active Comparator: Whey Protein Isolate 30g Serving of Whey Protein will be used daily in each subject. Intervention:Bi-Weekly blood draws will determine the effect on blood protein levels.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Genepro Generation 3
Arm Type
Active Comparator
Arm Description
1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
Arm Title
Whey Protein
Arm Type
Active Comparator
Arm Description
1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
Intervention Type
Dietary Supplement
Intervention Name(s)
Genepro Generation 3 Protein
Intervention Description
Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey Protein
Intervention Description
Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
Primary Outcome Measure Information:
Title
Blood Protein Levels
Description
Each participant in each group will have blood protein levels checked via blood draw at a WakeMed facility (based on participants geographic location). The target blood protein range is 6.1-8.7 g/dL this test is administered without fasting.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: Participants will be solicited to volunteer through WakeMed Bariatric Surgery Center (current patients) All participants must have normal blood protein levels prior to the study All participants must be six months post op (bariatric surgery) All participants must avoid any other protein supplementation during the trial period All participants are required to maintain a daily nutrition log All participants must have no milk/dairy allergies Age Eligibility: 25 years to 80 years (Adult) Sexes Eligibility for Study: ALL Only Accepts Healthy Volunteers EXCLUSION CRITERIA: No candidates with prior digestive distress disorders (IBS, Crones, etc.) Participants with any negative GI score, they will be excluded from the study Participants with abnormal blood protein levels at the time of study Unhealthy Volunteers Volunteers with compromised immune systems Volunteers younger than 25 years of age Volunteers older than 80 years of age Allergies to milk or lactose
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Brian M Parks, PHD
Phone
9196109893
Email
bparks@geneproprotein.net
First Name & Middle Initial & Last Name or Official Title & Degree
Zac Cain
Phone
9194551374
Email
zcain@musclegenresearch.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marina Maddaloni
Organizational Affiliation
WakeMed Bariatric Surgery Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Zac Cain
Organizational Affiliation
Genepro Protein, Inc.
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Brian Parks, PHD
Organizational Affiliation
Genepro Protein, Inc.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
John Bruce, MD
Organizational Affiliation
WakeMed Bariatric Surgery Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
LaMonica Daniel
Organizational Affiliation
WakeMed Health & Hospitals
Official's Role
Study Chair
Facility Information:
Facility Name
WakeMed Bariatric Surgery Center
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27511
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lamonica Daniel
First Name & Middle Initial & Last Name & Degree
Marina Maddaloni
First Name & Middle Initial & Last Name & Degree
Marina Maddaloni
First Name & Middle Initial & Last Name & Degree
John Bruce, MD
First Name & Middle Initial & Last Name & Degree
LaMonica Daniel
Facility Name
WakeMed
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27610
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
TBD TBD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein

We'll reach out to this number within 24 hrs